In inoperable patients medical treatment is well defined, and mainly includes the recently introduced pharmacological substances with impact on haemo dynamics and functional performance.
Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially fatal disease which occasionally occurs as a complication of acute pulmo nary embolism. The mechanisms leading to failure of thrombus resolution are not completely understood with only some risk factors identified. Vascular altera tions are present in the large and small vessel compart ment. Signs and symptoms of CTEPH are nonspecific, rendering diagnosis challenging. A VQ scan followed by computed tomography, magnetic resonance or conven tional pulmonary angiography is mandatory to confirm diagnosis and assess operability by a multidisciplinary team. Pulmonary endarterectomy remains the treat ment of choice in operable patients and results in sig nificantly improved haemodynamics and functional ca pacity.
Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is defined as symptomatic PH with persis tent pulmonary perfusion defects despite 3-6 months of adequate anticoagulation [1] . CTEPH is a rare com plication following an acute pulmonary embolism (PE) with an incidence reported up to 5% [2] . However, previous PE is not necessary for CTEPH diagnosis. Ob struction is composed of a central mechanical obstruc tion with potential for resection and a small vessel component of variable importance. In operable pa tients, CTEPH might be curable by surgical pulmonary endarterectomy [3] . In surgically inaccessible patients, medical therapy improves exercise capacity and haemodynamics [4] . CTEPH has been recently comprehensively summarised by the last WHO con ference on PH held in Nice [5] . We review CTEPH from epidemiology and pathogenesis to clinical presen tation, diagnosis and treatment.
Epidemiology
The prevalence of CTEPH varies between 3 to 30/1 mil lion in the population [6] . Among newly diagnosed cases only 60% to 75% have a history of acute PE. Thus, pathophysiological mechanisms other than PE might lead to CTEPH. The incidence of CTEPH following acute PE is unknown and varies greatly according to the setting. Numbers from 0.6% to 8.8% have been re ported [2, 7, 8] . In one study, the cumulative incidence of CTEPH was 1% at 6 months, 3.1% at 1 year and 3.8% at 2 years after acute PE [2] . Interestingly, no new CTEPH cases were noted after 2 years in the followup period up to 10 years. Predictors for CTEPH after acute PE are young age, large perfusion defects, multiple PE episodes and elevated pulmonary pressure at the time of PE, espe cially a right ventricular systolic pressure ≥50 mm Hg [9] . Additional risk factors for CTEPH include splenec tomy, thyroid replacement therapy, infected pacemaker lines, infected tunnelled catheter systems, chronic os teomyelitis, a history of malignancy, ventriculoatrial shunt, antiphospholipid antibodies/lupus anticoagu lant, inflammatory bowel disease, HLA polymorphism, nonO blood groups and fibrinogen variants resistant to fibrinolysis [10, 11] .
The development of CTEPH due to prothrombotic states is supported by the following observations: a strong association with venous thromboembolism and high levels of factor VIII [12] . Interestingly, even after a successful surgical pulmonary endarterectomy (PEA), the factor VIII level remains elevated [13] . In contrast, Factor V Leiden mutations, protein C and S deficiency and antithrombin III were not associated with CTEPH [14, 15] .
Haemodynamic parameters at CTEPH diagnosis predict survival. A mean pulmonary arterial pressure (mPAP) of ≥50 mm Hg is associated with a 2year mor
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Within the small vessel compartment, changes similar to pulmonary arterial hypertension (PAH) are observed in CTEPH [12] . Abnormal endothelial func tion, excessive proliferation of smooth muscle cells, migration of fibroblasts and inhibition of apoptosis in vascular smooth muscle cells lead to endothelial dys function, vascular remodelling and microthrombosis [25] . As in PAH, a persistent vasoconstrictive state, characterised by high levels of plasma endothelin1 and overexpression of type B endothelin receptors, may be present in CTEPH patients [26] .
The combination of proximal thrombus occlusion and vascular remodelling in nonoccluded vessels leads to elevated pulmonary vascular pressure and resist ance (PVR) with consecutive right heart hypertrophy and progressive right heart failure.
Clinical presentation
The main symptoms associated with CTEPH are non specific, such as progressive dyspnoea and exercise intolerance. They are often primarily considered to be associated to other states, like obstructive lung disease, deconditioning and obesity [5] . Haemodynamically, the cardiac output is limited by the high PVR. Minute ven tilation is augmented due to an increase of dead space [27] . Considering that 35% of patients do not have a history of acute PE, the diagnosis is challenging. In clinical examination, a fixed split or accentuated pul monic component of the S2 are common findings. Exer tality of >80%, a mPAP >30 mm Hg with a 3year mor tality of 90% [16] .
Echocardiography screening in patients after high and intermediate risk acute PE should be considered up to 2 years after the acute event [17] . In order to allocate resources to the patient who will profit most, it is suggested to focus surveillance programmes after acute PE on patients with mainly central vessel embo lisation and evidence of right ventricle dysfunction [18] .
Pathogenesis
In CTEPH patients, pulmonary vascular changes are observed at two levels.
The large vessel compartment is mainly affected by obstruction and remodelling of the pulmonary vascular bed by fibrous material, which may completely occlude or obstruct the lumen by webs and bands of scaring thrombus [19, 20] . The normal pathophysiological reac tion, driven by vascular endothelial growth factor and basic fibroblastic growth factor [21] , involves an en dothelial activation of the affected vessel with penetra tion of the thrombus in order to finally form vascular channels within the occluding clot [22] . In CTEPH patients, a combination of inappropriate angiogenesis [23] and inflammatory state (presence of proinflamma tory cytokine macrophage chemoattractant protein1 [24] impairs the thrombus resolution. Abnormal fibrin ogen types, failure to cleave fibrinogen by plasminogen [12] and fibrotic changes are also involved. 
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tional syncope and signs of RV failure are found in pro gressive disease. If a righttoleft shunt is present through a patent foramen ovale, cyanosis might be ob served.
CTEPH diagnosis
A ventilation perfusion (VQ) scan is the screening goal of choice to distinguish CTEPH from PH. With 96% sensitivity, a normal VQ scan allows CTEPH to be ruled out. VQ scans only require a limited radiation dose, do not depend on intravenous contrast agents and are of low cost. Despite these advantages, VQ scans seem to be underutilised in the evaluation of CTEPH. In one study, 43% of patients with precapillary PH did not have a VQ scan according to a quality report and thus might have been misclassified [28] .
In case of an abnormal VQ scan, pulmonary digital subtraction angiography is still considered as the golden standard to diagnose CTEPH. Pulmonary angio graphy accurately depicts the extension of the thromboembolic disease and, together with pulmonary haemodynamics, allows evaluation of operability for pulmonary endarterectomy (PEA).
Computed tomography pulmonary angiogram (CTPA) is performed in many centres to diagnose CTEPH in addition to VQ scans and pulmonary angio graphy. Some specialist teams even rely on this tech nique to base their decision on surgical accessibility of CTEPH. CTPA has the advantage of providing addi tional data on lung parenchyma, mediastinal lymph nodes, bronchial arteries and differential diagnosis. However, the diagnostic accuracy of this imaging tech nique depends on the experience of the radiologist and other interpreters, as various pathologies might present similarly as CTEPH, such as pulmonary artery sar coma, tumour emboli into the pulmonary artery (from renal, thyroid, testicular and uterine cancer), embolisa tion of hydatic cysts of the liver, pulmonary arteriitis (Takayashu, Behçet) or fibrous mediastinitis. Proximal lining thrombi associated with pulmonary arterial hy pertension can also mimic chronic thromboembolic dis ease. On the other hand, distal disease in segmental or subsegmental arteries may be missed in CTPA. How ever, in the latest generation of CT scanners, the resolu tion of the images allows a better evaluation of vascular wall thickness and surrounding structures. In compari son to conventional angiography, no need for catheter access makes CTPA more comfortable. Emerging tech niques, such as dual energy CT and lung perfusion MRI are additional promising tools in the diagnosis and op erability assessment of CTEPH. It is important to state that both pulmonary angiography and CTPA should be performed and interpreted in experienced PHcentres with access to surgical pulmonary endarterectomy.
In summary, according to the NICE PH conference 2013:
-VQ scan is recommended as screening tool for chronic thromboembolic disease in all patients with no obvious reason for precapillary PH. -Pulmonary angiography remains the gold stand ard for confirmation of chronic thromboembolic disease and evaluation of operability. -Highquality multidetector CTPA may be a suit able alternative to pulmonary angiography in cen tres with experience in CTEPH.
Surgical therapy
Pulmonary endarterectomy (PEA) has transformed CTEPH from a fatal disease to a potentially curable form of PH. PEA is classically performed via a median sternotomy to have access to both lungs and to install a cardiopulmonary bypass. Cooling to 20 °C allows deep hypothermic circulatory arrest (DHCA) to provide a clear operating field. The endarterectomy dissection plane should be circumferential in order to be able to dissect until the level of segmental and even subseg mental branches, a simple thrombectomy or embolec tomy without a true endarterectomy will not help to reduce the PVR (fig. 2) [29] . In experienced centres, the procedure is safe with a mortality below 5% [30, 31] . Successful outcomes for patients undergoing PEA have been reported in improvement of exercise capacity, haemodynamics (improving PVR by up to 80%) quality of life and life expectancy (90% survival rate at 5 years) [32] .
Recently, a prospective, controlled trial (PEACOG) showed that DHCA compared with cerebral perfusion during pulmonary endarterectomy surgery resulted in similar performance at 3 months and 1 year after surgery in the DHCA group [33] . Surprisingly, cogni tive function was even improved after the PEA, likely due to the improved cardiac output. 1year survival was 96%. The authors of the trial recommended DHCA as the best procedure, as 9 patients (from 74) had to cross over from antegrade cerebral perfusion to DHCA in order to keep the operating field clear.
Despite favourable outcomes in most patients, there are two major wellknown complications in the postoperative course of PEA: residual PH and reperfu sion lung injury [5] . Persistently elevated pulmonary pressure often occurs in combination with reperfusion lung injury. The emerging and improved technology of extracorporeal membrane oxygenation offers good salvage solution for both situations: venoarterial extra corporeal membrane oxygenation (ECMO) is used in case of haemodynamic instability. The right ventricle can be offloaded as well as PA pressures being reduced and therefore cardiac output and gas exchange are im proved. In case of reperfusion injury alone, conserva tive therapy or venovenous ECMO can be used [34] . Survival rates of these PEAcomplications up to 57% are reported.
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Since 2001, reports mainly from Japan emerged about innovative percutaneous pulmonary angioplasty done in patients which were noneligible for surgery due to comorbidities [35] [36] [37] [38] [39] . Multiple angioplasty pro cedures were necessary to achieve a significant reduc tion of the pulmonary vascular resistance and the stud ies were neither randomised nor controlled. Neverthe less, haemodynamic improvements were impressive as well as improvements in the 6minute walking dis tance and WHO functional class, and the procedure was safe, even in elderly patients [36] . Thus, this novel treatment option might be considered in CTEPHpa tients who are not eligible for surgery due to comorbid ities. Despite these promising reports, further con trolled trials and longterm data will be required in order to define the role of pulmonary angioplasty in the CTEPHtreatment algorithm and to address risks such as bleeding or vessel rupture and complications such as the occurrence of restenosis.
In conclusion, CTEPH is a surgically curable dis ease for some patients affected and we therefore under line the importance of the operability assessment through a multidisciplinary CTEPH specialised team.
Medical therapy
Lifelong anticoagulation is the foundation of treatment in all patients with CTEPH regardless of therapy and interventions [5] . Mostly, vitaminK antagonists are used in this indication. Although there are no trials specifically performed in CTEPH, it is reasonable to as sume that other anticoagulants such as heparines or direct inhibitors of FXa (e.g. rivaroxaban, apixaban) or thrombin (dabigatran) are similarly effective [40] . The former might more be used for shorttime bridging (e.g. perioperatively) the latters have the advantage that they can be given in fixed daily doses, do not need mon itoring, have less drugdrug and drugfood interactions and have demonstrated favourable bleedingriskto benefit ratio as demonstrated in several trials in patients with venous thromboembolism [40, 41] .
CTEPH patients are considered to be inoperable in up to 50% of cases. Reasons include distal disease, comorbidities (COPD, severe left ventricular dysfunc tion) and excessively high PVR [19] . For patients considered unsuitable for PEA or with postoperative persistent PH, pharmacological treatment with PH 
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REVIEW ARTICLE targeted therapies can be offered [5] . CTEPH and pulmonary arterial hypertension (PAH) share many pathogenetic features [42] . Thus, medical therapy as used for PAH (PAHtarget therapy) can be prescribed. Benefits of pulmonary vasodilators have been reported in various trials. BENEFiT was the first large RCT supporting medication with Bosentan in patients with inoperable forms of CTEPH. Bosentan given for 6 months reduced PVR by 24% compared to placebo but could not improve the 6minute walking distance [43] . More recently, clinically relevant primary end points have been reported by the large CHEST1 trial assessing a new drug class, the soluble guanylate cy clase stimulator, Riociguat [4] . After a cautious uptitra tion schema in order to avoid systemic vasodilatory ef fects and hypotension, patients receiving Riociguat had a significant improvement of 46 m in the 6minute walk distance and a reduction of their PVR by -31%. However, there was no effect on time to clinical worsen ing and the benefits were less pronounced among pa tients with persistent PH after PEA.
In summary, PEA remains the first therapeutic choice for patients with surgically accessible CTEPH. The evaluation for PEA must be made by an experi enced CTEPH team. Inoperable patients with distal disease, comorbidities or patients with persisting symptomatic PH after PEA should be treated with medical therapy and/or considered for pulmonary an gioplasty.
